Study on Canakinumab with Chemotherapy, Radiation, and Durvalumab for Lung Cancer

Inclusion Criteria

• Able to provide informed consent and follow study requirements.
• Age 18 or older.
• Diagnosed with Stage IIIA-C non-small cell lung cancer (NSCLC).
• Not suitable for surgery based on medical evaluations.
• Eligible for combined chemotherapy and radiation therapy.
• Confirmed NSCLC diagnosis through pathology review.
• Good overall health with an ECOG performance status of 0 or 1.
• Suitable for a specific dose of radiation therapy.
• Weigh more than 30 kg (about 66 pounds).
• Have normal organ and bone marrow function, as shown by specific blood tests.
• Women must be post-menopausal or have a negative pregnancy test if of childbearing potential.
• Willing to comply with study procedures and have a life expectancy of at least 6 months.

Exclusion Criteria

• Participating in another clinical trial with an investigational drug in the last 4 weeks.
• Enrolled in another lung cancer study, unless it's observational.
• Previous radiation that prevents further treatment.
• Cannot take durvalumab.
• Have certain autoimmune or inflammatory disorders, with some exceptions.
• Recent treatment with certain antibodies or immune-targeting drugs.
• Previous treatment with canakinumab.
• Use of systemic immunosuppressive medication recently, with some exceptions.
• Major surgery within 28 days before starting canakinumab.
• History of other cancers needing treatment in the past 3 years, with some exceptions.
• History of organ transplant.
• Severe concurrent illnesses, including psychiatric disorders, liver disease, active infections, or heart disease.
• Pregnant or breastfeeding women, or those not using effective birth control.
• Connective tissue disorders affecting the lungs or esophagus.
• Known primary immunodeficiency.
• Allergies to study drugs.
• Received a live vaccine within 3 months before starting the study.